Amphastar Pharmaceuticals, Inc.: directors' dealings · United States · SEC (Form 4)

About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ (United States) under the ticker AMPH. Its business model centers on the development, manufacturing, and commercialization of injectable, intranasal, and inhalation therapies, with a clear focus on technically complex generics, proprietary medicines, and advanced drug-delivery formats. From an international equity perspective, Amphastar is not a pure volume generic player; it is a formulation and manufacturing specialist that competes on regulatory execution, process know-how, and the ability to produce hard-to-make dosage forms at scale. The company was originally founded in California in the 1990s and was reorganized as a Delaware corporation in 2004. Its corporate headquarters are in Rancho Cucamonga, California, United States. Amphastar also highlights a multi-site industrial footprint, with manufacturing facilities in the United States, China, and Europe, plus a dedicated research center. The company emphasizes that its finished products are manufactured in the United States, an important point for investors assessing quality control, supply-chain resilience, and regulatory credibility. Amphastar’s commercial portfolio is broad for a specialized pharma company. Key marketed products include BAQSIMI® (nasal glucagon for severe hypoglycemia), Primatene® MIST (an OTC epinephrine inhalation aerosol), and a range of hospital-oriented injectables such as glucagon, epinephrine, iron sucrose, lidocaine, naloxone, and other specialty sterile products. Beyond its current revenue base, Amphastar is also developing biosimilars, peptide-based products, proteins, and novel delivery systems. That gives the company several potential growth drivers beyond its mature legacy products. Competitively, Amphastar occupies a niche position where manufacturing complexity and regulatory barriers matter. It operates in segments that blend branded specialty products with injectable generics, so profitability can be influenced by product mix, launch timing, and pricing pressure. The company’s capabilities in APIs, finished dosage manufacturing, and biologics support its efforts to defend and expand market share in selected therapeutic areas. Recent developments have been important. In 2025, Amphastar continued to expand BAQSIMI® distribution, including a global transition in distribution responsibilities and a separate exclusive distribution arrangement in Greater China. The company also secured FDA approvals for new products, including iron sucrose injection and teriparatide injection, reinforcing its pipeline-driven strategy. For investors in Europe and beyond, Amphastar stands out as a specialized U.S. NASDAQ-listed pharma manufacturer with a mix of commercial products, pipeline optionality, and execution-sensitive growth prospects.